Jfs Wealth Advisors, LLC Biocryst Pharmaceuticals Inc Transaction History

Jfs Wealth Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	BUY	$4.89 - $7.65 $24 - $38	5 Added 14.29%	40 $0
Q4 2023 Feb 07, 2024	SELL	$4.98 - $6.77 $164 - $223	-33 Reduced 48.53%	35 $0
Q3 2023 Nov 02, 2023	BUY	$6.71 - $7.92 $100 - $118	15 Added 28.3%	68 $0
Q2 2023 Aug 07, 2023	BUY	$6.96 - $8.81 $201 - $255	29 Added 120.83%	53 $0
Q1 2023 Apr 19, 2023	SELL	$7.94 - $11.84 $269 - $402	-34 Reduced 58.62%	24 $0
Q4 2022 Feb 13, 2023	SELL	$10.5 - $14.2 $31 - $42	-3 Reduced 4.92%	58 $0
Q3 2022 Oct 21, 2022	BUY	$10.79 - $14.81 $345 - $473	32 Added 110.34%	61 $1,000
Q2 2022 Aug 02, 2022	SELL	$7.89 - $17.88 $110 - $250	-14 Reduced 32.56%	29 $0
Q1 2022 May 02, 2022	BUY	$11.56 - $19.76 $358 - $612	31 Added 258.33%	43 $1,000
Q4 2021 Feb 03, 2022	BUY	$11.18 - $15.46 $134 - $185	12 New	12 $0

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Jfs Wealth Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Jfs Wealth Advisors, LLC with notifications on news.